Follow
Ugo De Giorgi
Ugo De Giorgi
Verified email at irst.emr.it
Title
Cited by
Cited by
Year
Pazopanib versus sunitinib in metastatic renal-cell carcinoma
RJ Motzer, TE Hutson, D Cella, J Reeves, R Hawkins, J Guo, P Nathan, ...
New England Journal of Medicine 369 (8), 722-731, 2013
21022013
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 …
T Powles, I Durán, MS Van der Heijden, Y Loriot, NJ Vogelzang, ...
The Lancet 391 (10122), 748-757, 2018
13852018
Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma
R Motzer, B Alekseev, SY Rha, C Porta, M Eto, T Powles, V Grünwald, ...
New England Journal of Medicine 384 (14), 1289-1300, 2021
12822021
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3 …
BI Rini, T Powles, MB Atkins, B Escudier, DF McDermott, C Suarez, ...
The Lancet 393 (10189), 2404-2415, 2019
9242019
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
MD Galsky, JÁA Arija, A Bamias, ID Davis, M De Santis, E Kikuchi, ...
The Lancet 395 (10236), 1547-1557, 2020
6822020
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study
B Escudier, C Porta, P Bono, T Powles, T Eisen, CN Sternberg, ...
Journal of Clinical Oncology 32 (14), 1412-1418, 2014
4802014
Plasma AR and abiraterone-resistant prostate cancer
A Romanel, DG Tandefelt, V Conteduca, A Jayaram, N Casiraghi, ...
Science translational medicine 7 (312), 312re10-312re10, 2015
4542015
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma …
T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ...
The Lancet Oncology 21 (12), 1574-1588, 2020
4052020
Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer
CN Sternberg, K Fizazi, F Saad, ND Shore, U De Giorgi, DF Penson, ...
New England Journal of Medicine 382 (23), 2197-2206, 2020
3862020
Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy—results from an …
K Fizazi, S Tjulandin, R Salvioni, JR Germŕ-Lluch, J Bouzy, D Ragan, ...
Journal of clinical oncology 19 (10), 2647-2657, 2001
3282001
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer
J Beyer, P Albers, R Altena, J Aparicio, C Bokemeyer, J Busch, ...
Annals of oncology 24 (4), 878-888, 2013
3222013
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
RJ Motzer, C Porta, NJ Vogelzang, CN Sternberg, C Szczylik, J Zolnierek, ...
The Lancet Oncology 15 (3), 286-296, 2014
2992014
Randomized phase II study evaluating Akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss
JS de Bono, U De Giorgi, DN Rodrigues, C Massard, S Bracarda, A Font, ...
Clinical Cancer Research 25 (3), 928-936, 2019
2942019
Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy
International Prognostic Factors Study Group
Journal of Clinical Oncology 28 (33), 4906-4911, 2010
2932010
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution …
V Conteduca, D Wetterskog, MTA Sharabiani, E Grande, ...
Annals of Oncology 28 (7), 1508-1516, 2017
2722017
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment
M Giuliano, A Giordano, S Jackson, KR Hess, U De Giorgi, M Mego, ...
Breast Cancer Research 13, 1-9, 2011
2582011
Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database
A Lorch, C Bascoul-Mollevi, A Kramar, L Einhorn, A Necchi, C Massard, ...
Journal of clinical oncology 29 (16), 2178-2184, 2011
2572011
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm …
RL Coleman, D Lorusso, C Gennigens, A González-Martín, L Randall, ...
The Lancet Oncology 22 (5), 609-619, 2021
2552021
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations
SK Pal, JE Rosenberg, JH Hoffman-Censits, R Berger, DI Quinn, ...
Cancer discovery 8 (7), 812-821, 2018
2492018
Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1
M Smith, J De Bono, C Sternberg, S Le Moulec, S Oudard, U De Giorgi, ...
Journal of Clinical Oncology 34 (25), 3005-3013, 2016
2392016
The system can't perform the operation now. Try again later.
Articles 1–20